Biotech fundraising must start with non-dilutive grant funding (SBIR/STTR) to de-risk the science before seeking equity. Your first equity round, typically $2M-$5M, requires a pitch deck centered on compelling experimental data and a clear regulatory path. Target only specialist life science investors who understand the long timelines and focus on funding a specific 18-24 month plan to reach the next major value-inflection milestone.
Key takeaways
- Aggressively pursue SBIR/STTR grants before seeking venture capital.
- Build your pitch deck around a single, powerful 'Core Data' slide that proves viability.
- Target only specialist life science VCs and angel investors with domain expertise.
- Your 'Use of Funds' must map directly to the next major de-risking milestone.
- Clearly articulate your regulatory pathway and IP strategy, even at the seed stage.
- Understand the valuation math: expect 20-35% dilution to fund an 18-24 month plan.
Your Biotech Startup Isn’t a SaaS Company. Don’t Fundraise Like One.
Raising capital for a health or life sciences company is a different sport. The timelines are longer, the capital requirements are higher, and the risks are fundamentally different. You aren’t just managing market risk; you are battling immense scientific and technical risk before your product ever sees a patient.
Generic fundraising advice will kill your company. You need a playbook built for the unique challenges of biotech: long R&D cycles, complex regulatory hurdles, and an IP-driven moat. This is your guide to navigating the early-stage funding landscape and securing the capital you need to get from the lab to a meaningful milestone.
Before you even think about selling equity, your first, non-negotiable stop is non-dilutive funding. For nearly every US-based biotech and life sciences company, this means government grants. Pursuing these is not optional; it’s the primary way to fund your earliest, riskiest R&D without giving up ownership.
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs are your lifeline. These are multi-phase grants from federal agencies like the National Institutes of Health (NIH) designed to move science from the lab toward commercialization.
Phase I: This is for feasibility and proof-of-concept. You can get $150,000 to $300,000 (and sometimes more) to validate your core hypothesis. The goal is to generate the key data that proves your idea isn’t just science fiction.
Phase II: If your Phase I is successful, you can apply for Phase II funding, which is much larger—often $1M to $2.5M—to fund major R&D and get you to a key preclinical milestone.
Winning these grants provides more than just cash. It’s a powerful signal to future investors that your science has been vetted and endorsed by expert reviewers.
Don't just write a grant; find a champion. Identify the Program Officer at the NIH institute most relevant to your work. Email…
Focu…
Frequently asked questions
- How much data do I really need for a biotech seed round?
- Enough to be compelling and show your mechanism of action is viable. At minimum, strong in-vitro data is required, but in-vivo animal model data is what truly de-risks the science and makes your company fundable at the seed stage.
- What is a typical valuation for a pre-seed/seed biotech company?
- Valuations vary widely based on team, indication, and data. A typical range for a first equity round is between a $8M and $15M post-money valuation, though truly hot platform companies can command more.
- Should our founding scientist be the CEO?
- Investors back scientist-CEOs if they demonstrate strong vision, leadership, and a willingness to learn the business side. It's crucial to show you can lead a company, not just a lab, and surround yourself with experienced operators.
- How long does a biotech seed fundraising process take?
- From the first outreach to money in the bank, expect the process to take 4-6 months, sometimes longer. Technical diligence by specialist VCs is thorough and cannot be rushed.
